Cancer represents a leading cause of death in the developed countries. The past 50 years have witnessed major progress in both laboratory medicine and clinical oncology that has translated into improved prognosis of cancer patients. From the humble beginnings as unrelated specialties, major advances in the understanding of molecular bases of cancer progression led to increased interactions between laboratory medicine and clinical (mostly medical) oncology. Laboratory medicine is now an integral part of the management of cancer patients. The many aspects of the role of laboratory medicine in clinical oncology include the determination of biomarkers that are used in establishing the diagnosis, predicting response to therapy or prognosis, study of the host response to tumor growth, detection of treatment toxicity and determining the concentrations of anticancer drugs.

Department of Oncology Palacký University Medical School and Teaching Hospital Fakultní nemocnice Olomouc Czech Republic

Citace poskytuje Crossref.org

The Role of Neopterin and Interleukin-6 Detection in Saliva and Plasma in Oral and Oropharyngeal Cancer Patients: A Prospective Study

Association of the combined parameters including the frequency of primary cilia, PD-L1, Smoothened protein, membranous β-catenin and cytoplasmic β-catenin expression with the outcome of patients with clear cell renal cell carcinoma

Circulating tumor DNA measurement: a new pillar of medical oncology?

Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients

ABC Transporters and Their Role in the Neoadjuvant Treatment of Esophageal Cancer

Dysregulation of KRAS signaling in pancreatic cancer is not associated with KRAS mutations and outcome

MALDI Orbitrap Mass Spectrometry Profiling of Dysregulated Sulfoglycosphingolipids in Renal Cell Carcinoma Tissues

Neopterin as a biomarker of immune response in cancer patients

Risk factors of atherosclerosis during systemic therapy targeting vascular endothelial growth factor